DENALI THERAPEUTICS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 18.59 USD | +0.70% |
|
-3.23% | -13.37% |
Financials (USD)
| Sales 2024 * | 45.66M | Sales 2025 * | 107M | Capitalization | 2.65B |
|---|---|---|---|---|---|
| Net income 2024 * | -426M | Net income 2025 * | -464M | EV / Sales 2024 * | 30.5 x |
| Net cash position 2024 * | 1.25B | Net cash position 2025 * | 1.05B | EV / Sales 2025 * | 15 x |
| P/E ratio 2024 * |
-6.76
x | P/E ratio 2025 * |
-6.78
x | Employees | 375 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 86.32% |
More Fundamentals
* Assessed data
More news
Latest transcript on Denali Therapeutics Inc.
More recommendations
More press releases
More news
| 1 day | +0.70% | ||
| 1 week | -3.23% | ||
| Current month | +0.16% | ||
| 1 month | +15.04% | ||
| 3 months | -10.88% | ||
| 6 months | -2.00% | ||
| Current year | -13.37% |
1 week
17.93
19.78
1 month
16.7120.91
Current year
14.5623.52
1 year
14.5633.31
3 years
14.5679.70
5 years
12.3993.94
10 years
12.3293.94
| Managers | Title | Age | Since |
|---|---|---|---|
Alexander Schuth
FOU | Founder | 50 | 13-10-13 |
Ryan Watts
FOU | Founder | 48 | 13-10-13 |
Joe Lewcock
CTO | Chief Tech/Sci/R&D Officer | - | 19-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Vicki Sato
CHM | Chairman | 75 | 15-03-31 |
Jay Flatley
BRD | Director/Board Member | 71 | 15-03-31 |
David Schenkein
BRD | Director/Board Member | 66 | 15-03-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.31% | 0 M€ | 0.00% | - | |
| 0.31% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 18.56 | +0.54% | 1,762,397 |
| 24-05-30 | 18.46 | +2.33% | 1,026,133 |
| 24-05-29 | 18.04 | -4.55% | 820,658 |
| 24-05-28 | 18.9 | -1.61% | 671,862 |
| 24-05-24 | 19.21 | -0.26% | 813,112 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotes
Denali Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing a portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases and lysosomal storage disease. The Company has a portfolio of both small molecule and biotherapeutic medicines, comprising seven product candidates in clinical development across seven indications as well as preclinical therapeutic candidates. Its three late-stage development programs include tividenofusp alfa (DNL310) for mucopolysaccharidosis II (MPS II); BIIB122/DNL151 (LRRK2 inhibitor) for Parkinsonâs disease; and DNL343 (eIF2B activator) for amyotrophic lateral sclerosis (ALS). SAR443820/DNL788 (RIPK1 inhibitor) is being evaluated in a Phase II study for multiple sclerosis (MS). In addition, it has a Phase I/II study of TAK-594/DNL593 for frontotemporal dementia-granulin (FTD-GRN) and a Phase I/II study of DNL126 for MPS IIIA (Sanfilippo syndrome).
Calendar
2024-06-04
- Jefferies Global Healthcare Conference
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
18.56
USD
Average target price
38.67
USD
Spread / Average Target
+108.33%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -13.37% | 2.65B | |
| +11.91% | 118B | |
| +11.60% | 106B | |
| -4.68% | 24.28B | |
| -0.82% | 21.96B | |
| -10.12% | 18.16B | |
| -42.12% | 16.37B | |
| -17.47% | 15.56B | |
| +2.77% | 13.63B | |
| +34.58% | 12.27B |
- Stock Market
- Equities
- DNLI Stock
